Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With MKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting
Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With MKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting
Elicio Therapeutics 於 5 月 23 日在 2024 年 ASCO 年會上公佈了正在進行的 AMPLIFY-7P 1a 期研究的初步數據，該研究針對 MKRAS 驅動的實體瘤患者 ELI-002 7P
-
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels
- ELI-002 7P generated an mKRAS-specific T cell response in 100% of patients including responses targeting all mKRAS mutations enrolled (G12D, V, R and G13D)
- mKRAS-specific T cells were polyfunctional with 66.7% (4/6) of evaluable patients having both CD8+ and CD4+ responses at the 4.9 mg Phase 2 dose level
- Tumor biomarker reductions were observed in 5/7 (71%) of evaluable patients at the 4.9 mg Phase 2 dose level
- ELI-002 7P was shown to induce antigen-spreading with increased T cell responses targeting non-immunizing, personalized tumor neoantigens in 6/6 (100%) of evaluable patients at the 4.9 mg Phase 2 dose level
-
作爲單一療法使用的 ELI-002 7P 耐受性良好，能夠產生與基線水平相比約 100 倍的 MKRAS 特異擴大 T 細胞反應
- ELI-002 7P 在 100% 的患者中產生了 MKRAS 特異性 T 細胞反應，包括針對所有入組的 MKRA 突變（G12D、V、R 和 G13D）的反應
- MKRAS 特異性 T 細胞具有多功能性，66.7% (4/6) 的可評估患者在 4.9 mg 的 2 期劑量水平下同時出現 CD8+ 和 CD4+ 反應
- 在 4.9 mg 的 2 期劑量水平下，有 5/7 (71%) 的可評估患者觀察到腫瘤生物標誌物降低
- 在 4.9 mg 2 期劑量水平下，在 6/6 (100%) 的可評估患者中，ELI-002 7P 被證明可誘導抗原擴散，增加靶向非免疫性、個性化腫瘤新抗原的 T 細胞反應